PRAT4A Inhibitors
PRAT4A inhibitors are a class of chemical compounds that specifically target the PRAT4A protein, which plays a key role in the assembly and trafficking of Toll-like receptors (TLRs) within the endoplasmic reticulum. PRAT4A, also known as protein associated with TLR4, is essential for the proper maturation and localization of TLRs, which are integral to the innate immune response and recognition of pathogen-associated molecular patterns. By facilitating the movement of TLRs from the endoplasmic reticulum to the cell surface or endosomal compartments, PRAT4A ensures that these receptors are correctly positioned to detect external signals. Inhibiting PRAT4A disrupts this trafficking process, potentially altering the downstream signaling pathways linked to TLRs.
The design of PRAT4A inhibitors is based on an in-depth understanding of the protein's role in the endoplasmic reticulum and its interaction with TLRs. These inhibitors are typically developed to bind to specific sites on PRAT4A that are crucial for its function, such as domains involved in protein-protein interactions or regions responsible for facilitating receptor trafficking. Researchers utilize various biochemical and structural biology techniques to elucidate the precise mechanisms by which PRAT4A operates, allowing them to design inhibitors that can selectively interfere with its activity. Through the inhibition of PRAT4A, these compounds offer a way to modulate the regulation of TLR maturation and trafficking, providing insights into the broader processes of protein trafficking, receptor assembly, and cellular signaling. The study of PRAT4A inhibition is valuable for understanding its role in maintaining the balance of protein function and cellular communication within complex biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may downregulate PRAT4A expression by altering histone acetylation and thus decreasing the transcriptional activity of genes within affected chromatin regions. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound could decrease PRAT4A expression by inducing DNA hypomethylation, thereby leading to the suppression of gene transcripts that are normally upregulated by methylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin (Sirolimus) may inhibit PRAT4A synthesis by downregulating mTOR signaling, which plays a central role in controlling the translation of a subset of mRNAs encoding components of the protein synthesis machinery. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol could reduce PRAT4A expression by decreasing the activity of specific transcription factors that are responsible for the upregulation of this proteasomal gene under oxidative stress conditions. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin may suppress PRAT4A expression by downregulating NF-κB signaling, leading to reduced transcriptional initiation of genes involved in inflammatory response, which can include proteasomal genes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 may inhibit PRAT4A expression by blocking PI3K/Akt signaling, which would disrupt downstream transcriptional processes that can include the expression of proteasomal genes. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid might suppress PRAT4A transcription by binding to retinoic acid receptors that interact with gene promoters, leading to decreased transcriptional activity of genes involved in cell cycle control. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate could downregulate PRAT4A expression by increasing global levels of histone acetylation, thereby reducing the transcriptional efficiency of genes associated with protein degradation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG has the potential to reduce PRAT4A expression by hindering the proteasomal degradation pathway, leading to a cellular shift towards the lysosomal degradative system. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 may inhibit PRAT4A expression by blocking MEK1/2, leading to the suppression of the ERK pathway and consequently decreasing the transcription of genes encoding proteasomal constituents. | ||||||